Cipher Pharmaceuticals Inc. (NASDAQ: CPHR; TSX:CPH) ("Cipher" or "the Company") today announced it has strengthened its Canadian dermatology portfolio by acquiring the Canadian rights to Vaniqa ® and ...
Please provide your email address to receive an email when new articles are posted on . Cipher Pharmaceuticals announced it has acquired the Canadian commercialization rights to Vaniqa and Actikerall ...
Almirall has received a positive recommendation from seven European regulators for Actikerall, its new treatment for precancerous growths on the skin. Almirall has received a positive recommendation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results